These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31899994)

  • 1. 'Prototypical' proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting.
    Musella A; Fresegna D; Rizzo FR; Gentile A; De Vito F; Caioli S; Guadalupi L; Bruno A; Dolcetti E; Buttari F; Bullitta S; Vanni V; Centonze D; Mandolesi G
    Expert Opin Ther Targets; 2020 Jan; 24(1):37-46. PubMed ID: 31899994
    [No Abstract]   [Full Text] [Related]  

  • 2. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.
    Mandolesi G; De Vito F; Musella A; Gentile A; Bullitta S; Fresegna D; Sepman H; Di Sanza C; Haji N; Mori F; Buttari F; Perlas E; Ciotti MT; Hornstein E; Bozzoni I; Presutti C; Centonze D
    J Neurosci; 2017 Jan; 37(3):546-561. PubMed ID: 28100738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.
    Skundric DS; Cruikshank WW; Montgomery PC; Lisak RP; Tse HY
    Cytokine; 2015 Oct; 75(2):234-48. PubMed ID: 25703787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System.
    Kolbinger F; Huppertz C; Mir A; Padova FD
    Curr Drug Targets; 2016; 17(16):1882-1893. PubMed ID: 26953244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis.
    Miller ED; Dziedzic A; Saluk-Bijak J; Bijak M
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31284389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IL-1β phenomena in neuroinflammatory diseases.
    Mendiola AS; Cardona AE
    J Neural Transm (Vienna); 2018 May; 125(5):781-795. PubMed ID: 28534174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the IL-1 system in experimental autoimmune encephalomyelitis and multiple sclerosis: Breaking the vicious cycle between IL-1β and GM-CSF.
    Paré A; Mailhot B; Lévesque SA; Lacroix S
    Brain Behav Immun; 2017 May; 62():1-8. PubMed ID: 27432634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine networks in multiple sclerosis: lost in translation.
    Codarri L; Fontana A; Becher B
    Curr Opin Neurol; 2010 Jun; 23(3):205-11. PubMed ID: 20442570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis.
    Chitnis T; Imitola J; Khoury SJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):11-26. PubMed ID: 15777201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies.
    Bjelobaba I; Savic D; Lavrnja I
    Curr Pharm Des; 2017; 23(5):693-730. PubMed ID: 27981909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
    Lin CC; Edelson BT
    J Immunol; 2017 Jun; 198(12):4553-4560. PubMed ID: 28583987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis.
    Srinivasan M; Lahiri DK
    Expert Opin Ther Targets; 2015 Apr; 19(4):471-87. PubMed ID: 25652642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
    Lee DH; Linker RA
    Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology.
    Mc Guire C; Prinz M; Beyaert R; van Loo G
    Trends Mol Med; 2013 Oct; 19(10):604-13. PubMed ID: 24007818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of B cell-targeted therapies in multiple sclerosis.
    Boster A; Ankeny DP; Racke MK
    Drugs; 2010 Dec; 70(18):2343-56. PubMed ID: 21142258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of IL-27 in multiple sclerosis?
    Fitzgerald DC; Rostami A
    Expert Opin Biol Ther; 2009 Feb; 9(2):149-60. PubMed ID: 19236245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases.
    Palomo J; Dietrich D; Martin P; Palmer G; Gabay C
    Cytokine; 2015 Nov; 76(1):25-37. PubMed ID: 26185894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting IL-1 in Sjögren's syndrome.
    Yamada A; Arakaki R; Kudo Y; Ishimaru N
    Expert Opin Ther Targets; 2013 Apr; 17(4):393-401. PubMed ID: 23320392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Properties of Cytokines in Multiple Sclerosis: Pros and Cons.
    Wang K; Song F; Fernandez-Escobar A; Luo G; Wang JH; Sun Y
    Am J Med Sci; 2018 Dec; 356(6):552-560. PubMed ID: 30447707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.